Komori
Share Issuance and Disposal4882Perseus Proteomics Inc.Pharmaceuticals

Notice Concerning the Monthly Exercise Status of Stock Acquisition Rights with Exercise Price Adjustment Provisions

In March 2026, 19,500 Series 29 share acquisition rights with exercise price adjustment provisions were exercised, resulting in the delivery of 1,950,000 new shares. As of month-end, 14,299 share acquisition rights remained unexercised.

Worth reading
80Important
Scored from 2 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
1950000
Shares
Wording
Definitive
How definitive the wording is.

Details of issuance or disposal

Monthly exercise status of stock acquisition rights with an exercise price adjustment clause

発行・処分する株式数1,950,000Shares

1,950,000 shares (new shares)

発行済株式総数

Exercise ratio under the exercise restriction: 13.22% (1,950,000 shares delivered / 14,749,500 listed shares as of the payment date for the issuance)

The dilution rate shows what proportion the newly issued shares represent of the existing shares. The higher the proportion, the more the value and voting rights per share are diluted.

Terms of the stock acquisition rights
Exercise price
Exercise prices during the subject month were ¥191, ¥214 and ¥265. Adjustment provisions apply. The adjustment floor is Not disclosed.
Number of Stock Acquisition Rights
Total issued: 36,800 rights; exercised during the subject month: 19,500 rights; unexercised at the end of the subject month: 14,299 rights
Basis for determining the amount to be paid
The exercise price on 10 March 2026 was adjusted to ¥265, the closing price on the issuance resolution date (17 December 2025).
Procedures under the Corporate Code of Conduct
The status of the exercise restriction and the conditions for exercising beyond the restriction are described.
Most recent equity financing
Timing Issued on 5 January 2026 / Type Stock Acquisition Rights with Exercise Price Adjustment Clauses / Amount Not disclosed
Details of issuance or disposal
ItemDetails
Type of issuance or disposalMonthly exercise status of stock acquisition rights with an exercise price adjustment clause
Number of shares to be issued or disposed of1,950,000 shares (new shares)
Dilution RateExercise ratio under the exercise restriction: 13.22% (1,950,000 shares delivered / 14,749,500 listed shares as of the payment date for the issuance)
Total number of issued shares15,049,600 shares (as of the end of the month preceding the subject month) → 17, - Not disclosed
Basis for determining the amount to be paidThe exercise price on 10 March 2026 was adjusted to ¥265, the closing price on the issuance resolution date (17 December 2025).
Exercise priceExercise prices during the subject month were ¥191, ¥214 and ¥265. Adjustment provisions apply. The adjustment floor is Not disclosed.
Number of Stock Acquisition RightsTotal issued: 36,800 rights; exercised during the subject month: 19,500 rights; unexercised at the end of the subject month: 14,299 rights
Procedures under the Corporate Code of ConductThe status of the exercise restriction and the conditions for exercising beyond the restriction are described.
Most recent equity financingTiming Issued on 5 January 2026 / Type Stock Acquisition Rights with Exercise Price Adjustment Clauses / Amount Not disclosed
Items this document does not state (19)
Issue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateIntended allotteeIntended allottee's holding policyExercise periodTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioMajor shareholders after the offeringImpact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

With respect to the exercise on 10 March 2026, the exercise price was adjusted to ¥265, the closing price on the date of the issuance resolution, and the conditions for exercising beyond the restriction under the Enforcement Rules of the Securities Listing Regulations were met. Accordingly, the rights were exercised in excess of the exercise restriction.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Concerning the Monthly Exercise Status of Stock Acquisition Rights with Exercise Price Adjustment Provisions | Perseus Proteomics Inc. (4882) timely disclosure | Komori